Wikipedia:Version 1.0 Editorial Team/Pharmacology articles by quality log

This is a log of operations by a bot. The contents of this page are unlikely to need human editing. In particular, links should not be disambiguated as this is a historical record.

July 24, 2024

Reassessed

Brincidofovir (talk) reassessed. Quality rating changed from Start-Class to C-Class. (rev · t)

Assessed

3,4-Pr-PipVP (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Pharmacology Research & Perspectives (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Draft:Shamitha Kusum Perera (talk) assessed. Importance assessed as NA-Class. (rev · t)

July 23, 2024

Renamed

Tetrahydrofuranitazene renamed to Ethyleneoxynitazene.

Reassessed

3-bromopyruvic acid (talk) reassessed. Importance rating changed from Low-Class to NA-Class. (rev · t)
Caffeine citrate (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)
Fluperlapine (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
URB597 (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed

3-Me-PVP (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
4'-Chlorodeschloroalprazolam (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Ethyleneoxynitazene (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

Removed

Draft:Afshin Mohammadi Bardbori (talk) removed.

July 22, 2024

Reassessed

Antiandrogens in the environment (talk) reassessed. Quality rating changed from Stub-Class to C-Class. (rev · t)

Assessed

A-PBITMO (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
ADMB-3TMS-PRINACA (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
CUMYL-3TMS-PRINACA (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
MDMB-BINACA (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

July 21, 2024

Reassessed

Dequalinium (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t) Importance rating changed from Unknown-Class to Low-Class. (rev · t)
Phonophoresis (talk) reassessed. Quality rating changed from Start-Class to Redirect-Class. (rev · t)

July 20, 2024

Assessed

Marisa Haetzman (talk) assessed. Quality assessed as Start-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

July 19, 2024

Reassessed

Bulevirtide (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)
Sugemalimab (talk) reassessed. Quality rating changed from Stub-Class to Start-Class. (rev · t)

Assessed

Secbutonitazene (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)
Tetrahydrofuranitazene (talk) assessed. Quality assessed as Stub-Class. (rev · t) Importance assessed as Low-Class. (rev · t)

July 18, 2024

Assessed

Draft:Antonio Ibarra (talk) assessed. Importance assessed as NA-Class. (rev · t)